A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Inclusion Criteria:

* Recipient age \>= 18 years of age
* The recipient is CMV seropositive
* The recipient is planned to receive an allogeneic peripheral blood stem cell graft
* The recipient is planned to receive fludarabine, melphalan, and total body irradiation for the transplant conditioning regimen
* The recipient is planned to receive micro-dose methotrexate, tacrolimus, and mycophenolate mofetil for acute graft versus host disease (GvHD) prophylaxis
* The recipient has an expected hematopoietic cell transplantation-comorbidity index (HCT-CI) score of 4 or less based upon the data available at the time of eligibility assessment
* The recipient must understand the investigational nature of this study and has signed an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedures
* The donor is CMV seronegative or seropositive
* The donor is 8/8 human leukocyte antigen (HLA) (DR-B1, A, B, C) matched to the recipient
* The donor is willing and able to donate peripheral blood mononuclear cells in addition to peripheral blood stem cells
* The donor is willing to sign informed consent

Exclusion Criteria:

* The recipient is CMV seronegative
* The recipient is planned to receive T cell depletion in vivo (anti-thymocyte globulin \[ATG\], alemtuzumab, post-transplant cyclophosphamide) or ex vivo (alpha-beta T cell depleted or CD34+ selected grafts) as acute GvHD prophylaxis
* The graft source is cord blood or bone marrow
* The donor or recipient has HLA DRB1\*0301 or DRB1\*1501 alleles
* The recipient has a very high disease risk index (DRI) based upon the data available at the time of eligibility assessment
* The recipient has a medical, behavioral, or social condition which in the opinion of the investigators would preclude compliance with the study